#United States #Pleasanton #10x Genomics #Parse Biosciences #ATAC-Seq

10x Genomics Secures a Major Legal Victory Against Parse Biosciences

In a significant legal ruling, 10x Genomics (Nasdaq: TXG) has secured a permanent injunction against Parse Biosciences regarding its planned ATAC and ATAC-Multiome Single Cell products. This verdict, reached through a consent agreement in the United States District Court for the District of Delaware on February 25, 2025, prevents Parse from producing or selling these products, which were found to infringe upon 10x's ATAC-seq patents. This decision came just one week before the trial was set to commence, highlighting the strength and validity of 10x Genomics' patent portfolio.

The resolution was welcomed by Eric S. Whitaker, the Chief Legal Officer of 10x Genomics, who emphasized that this ruling underscores the robustness of the company's innovation safeguards. Whitaker stated, "This development further validates the strength of our broad patent portfolio, which helps protect and preserve the world-class innovation engine at 10x." The company remains focused on defending its intellectual property rights and continues to engage in ongoing litigation related to Parse's gene expression products, with additional patents still under appeal.

Despite this victory, the case underscores the larger landscape of competition in the field of single-cell and spatial biology. 10x Genomics has established itself as a leader in this competitive market, providing essential tools and technologies to enhance biological understanding and healthcare solutions. This ruling is a part of the company's ongoing strategy to defend its innovations vigorously and ensure that its breakthroughs remain protected from infringement.

10x Genomics' technology is pivotal for advancing research across various biological fields, including oncology, immunology, and neuroscience. Their integrated solutions, which encompass instruments, consumables, and software, allow researchers to dissect complex biological systems at unprecedented resolutions. By safeguarding its patents, 10x aims to secure its position as a key player in life sciences and facilitate groundbreaking discoveries that can transform our understanding of health and disease.

The recent injunction against Parse signifies a pivotal moment for 10x Genomics, not only in the current litigation landscape but also in the broader context of intellectual property rights in biotechnology. As the legal battles continue, the outcomes could have far-reaching implications for research and development within the sector, influencing how companies protect their innovations in an increasingly competitive atmosphere.

As the trial regarding 10x’s remaining patent infringement claims against Parse has been stayed pending appeals, the biotechnology community will be watching closely. The outcome of this case could set precedents for similar disputes in the future, particularly as biotechnological advancements rapidly evolve. 10x Genomics remains committed to its mission of empowering researchers worldwide and continuing to lead in life science technologies.